Photobiomodulation and Parkinson

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-29

Study Completion Date

2018-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to assess the effects of transcranial photobiomodulation in patients with Parkinson's disease (PD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Parkinson´s Disease, Aerobic Exercise and Photobiomodulation

NCT05152706

Parkinson Disease

COMPLETED NA

Transcranial Photobiomodulation With Patients With Parkinson's Disease

NCT06729125

Parkinson Disease

COMPLETED NA

Sublingual Photobiomodulation in Parkinson's Disease

NCT04028817

Parkinson Disease

UNKNOWN NA

Effects of Transcranial Direct Current Stimulation on Postural Control

NCT03759132

Parkinson Disease

COMPLETED PHASE2/PHASE3

Light Therapy in Parkinson's Disease

NCT02072642

Parkinson's Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thirty-five patients with idiopathic PD were randomly assigned to a photobiomodulation (n=17, \[mean±SD\] 72±7 years) or sham group (n=18, 70±8 years) during 9 weeks (2 sessions/week). The primary endpoint was the motor portion of the Movement Disorders Society-United PD Rating Scale. Secondary endpoints were the Scales for Outcomes in PD, static posturography, walking ability (ten-meter walk test \[TMWT\]) and functional mobility (timed up and go \[TUG\] test).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Photobiomodulation group

17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).

Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks.

Group Type EXPERIMENTAL

Transcranial photobiomodulation

Intervention Type OTHER

Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Sham group

18 Parkinson´s disease patients were randomly assigned to the sham group.

Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group).

Group Type SHAM_COMPARATOR

Transcranial photobiomodulation

Intervention Type OTHER

Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial photobiomodulation

Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LEDs

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having been diagnosed with idiopathic PD.
* Stage 1-2 on the Hoehn and Yahr Scale.
* Having no neurological condition other than PD.
* Being able to stand for 2 minutes and walk 10 meters without assistance.
* Having no severe dyskinesias or "ON-OFF" phases.

Eligible Sex

ALL

Accepts Healthy Volunteers

No